Unveiling 8 Analyst Insights On NovoCure
Unveiling 8 Analyst Insights On NovoCure
公佈關於NovoCure的8條分析師見解
Throughout the last three months, 8 analysts have evaluated NovoCure (NASDAQ:NVCR), offering a diverse set of opinions from bullish to bearish.
在過去的三個月中，有8位分析師對NovoCure（納斯達克股票代碼：NVCR）進行了評估，提供了從看漲到看跌的不同觀點。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
下表彙總了他們最近的評級，闡明瞭過去30天內情緒的變化，並將其與前幾個月進行了比較。
In the assessment of 12-month price targets, analysts unveil insights for NovoCure, presenting an average target of $24.0, a high estimate of $42.00, and a low estimate of $15.00. Observing a downward trend, the current average is 1.19% lower than the prior average price target of $24.29.
在評估12個月目標股價時，分析師公佈了對NovoCure的見解，將平均目標股價定爲24.0美元，最高估計爲42.00美元，低估值爲15.00美元。從下降趨勢來看，當前的平均價格比之前的平均目標價24.29美元低1.19％。
Understanding Analyst Ratings: A Comprehensive Breakdown
了解分析師評級：全面細分
A clear picture of NovoCure's perception...
通過對近期分析...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。